Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients
Abstract Background Squid, as Onyx, is an ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolic agent developed for neuroradiologic interventions with poor application in abdominal district. Our aim was to evaluate safety, complications, and efficacy of transcatheter embolization using the tw...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2019-02-01
|
| Series: | CVIR Endovascular |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s42155-019-0051-7 |
| _version_ | 1828233575180271616 |
|---|---|
| author | Massimo Venturini Carolina Lanza Paolo Marra Anna Colarieti Marta Panzeri Luigi Augello Simone Gusmini Marco Salvioni Francesco De Cobelli Alessandro Del Maschio |
| author_facet | Massimo Venturini Carolina Lanza Paolo Marra Anna Colarieti Marta Panzeri Luigi Augello Simone Gusmini Marco Salvioni Francesco De Cobelli Alessandro Del Maschio |
| author_sort | Massimo Venturini |
| collection | DOAJ |
| description | Abstract Background Squid, as Onyx, is an ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolic agent developed for neuroradiologic interventions with poor application in abdominal district. Our aim was to evaluate safety, complications, and efficacy of transcatheter embolization using the two available formulations Squid-18 and 12, in 30 patients affected by different abdominal diseases. Results Transcatheter embolization with Squid, combined with other embolic agents, as poly vinyl alcohol (PVA) particles, coils and amplatzer plugs, or alone (type 2 endoleak), was performed in 30 patients, as follows: 10 portal vein embolizations (PVEs), 6 arteriovenous malformations (AVMs), 5 visceral artery aneurysms (VAAs), 4 type 2 endoleaks, 3 preoperative embolizations, 1 acute arterial bleeding, 1 female varicocele. Squid was always administered using dimethyl sulfoxide (DMSO) compatible microcatheters. Technical success, 30-day clinical success and complications were assessed. Technical success was 90%. 3 patients (2 AVMs, 1 VAA) required re-intervention successfully performed in all cases. Major complications, cases of microcatheter entrapment and DMSO-related poor pain control were not recorded. 30-day clinical success was 93.3%: in 2 patients submitted to PVE a sufficient future liver remnant (FLR) hypertrophy was not achieved. Conclusion Squid was successfully used with low complication rate in many abdominal diseases showing a valid embolic action either combined with other embolic agents or alone in type 2 endoleak. The availability of different formulations (Squid-18 and Squid-12) variable for viscosity makes Squid preferable to Onyx as EVOH-based liquid embolic agent, even though comparable studies in different abdominal districts with a larger cohort of patients will be necessary. |
| first_indexed | 2024-04-12T19:41:40Z |
| format | Article |
| id | doaj.art-13abf28b34fd4c39b3b589e1bda3304f |
| institution | Directory Open Access Journal |
| issn | 2520-8934 |
| language | English |
| last_indexed | 2024-04-12T19:41:40Z |
| publishDate | 2019-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | CVIR Endovascular |
| spelling | doaj.art-13abf28b34fd4c39b3b589e1bda3304f2022-12-22T03:19:03ZengSpringerOpenCVIR Endovascular2520-89342019-02-012111310.1186/s42155-019-0051-7Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patientsMassimo Venturini0Carolina Lanza1Paolo Marra2Anna Colarieti3Marta Panzeri4Luigi Augello5Simone Gusmini6Marco Salvioni7Francesco De Cobelli8Alessandro Del Maschio9Department of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleDepartment of Radiology, Scientific Institute H S. RaffaeleAbstract Background Squid, as Onyx, is an ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolic agent developed for neuroradiologic interventions with poor application in abdominal district. Our aim was to evaluate safety, complications, and efficacy of transcatheter embolization using the two available formulations Squid-18 and 12, in 30 patients affected by different abdominal diseases. Results Transcatheter embolization with Squid, combined with other embolic agents, as poly vinyl alcohol (PVA) particles, coils and amplatzer plugs, or alone (type 2 endoleak), was performed in 30 patients, as follows: 10 portal vein embolizations (PVEs), 6 arteriovenous malformations (AVMs), 5 visceral artery aneurysms (VAAs), 4 type 2 endoleaks, 3 preoperative embolizations, 1 acute arterial bleeding, 1 female varicocele. Squid was always administered using dimethyl sulfoxide (DMSO) compatible microcatheters. Technical success, 30-day clinical success and complications were assessed. Technical success was 90%. 3 patients (2 AVMs, 1 VAA) required re-intervention successfully performed in all cases. Major complications, cases of microcatheter entrapment and DMSO-related poor pain control were not recorded. 30-day clinical success was 93.3%: in 2 patients submitted to PVE a sufficient future liver remnant (FLR) hypertrophy was not achieved. Conclusion Squid was successfully used with low complication rate in many abdominal diseases showing a valid embolic action either combined with other embolic agents or alone in type 2 endoleak. The availability of different formulations (Squid-18 and Squid-12) variable for viscosity makes Squid preferable to Onyx as EVOH-based liquid embolic agent, even though comparable studies in different abdominal districts with a larger cohort of patients will be necessary.http://link.springer.com/article/10.1186/s42155-019-0051-7Transcatheter embolizationSquidPortal vein embolizationVisceral aneurysmArteriovenous malformationType 2 endoleak |
| spellingShingle | Massimo Venturini Carolina Lanza Paolo Marra Anna Colarieti Marta Panzeri Luigi Augello Simone Gusmini Marco Salvioni Francesco De Cobelli Alessandro Del Maschio Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients CVIR Endovascular Transcatheter embolization Squid Portal vein embolization Visceral aneurysm Arteriovenous malformation Type 2 endoleak |
| title | Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients |
| title_full | Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients |
| title_fullStr | Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients |
| title_full_unstemmed | Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients |
| title_short | Transcatheter embolization with Squid, combined with other embolic agents or alone, in different abdominal diseases: a single-center experience in 30 patients |
| title_sort | transcatheter embolization with squid combined with other embolic agents or alone in different abdominal diseases a single center experience in 30 patients |
| topic | Transcatheter embolization Squid Portal vein embolization Visceral aneurysm Arteriovenous malformation Type 2 endoleak |
| url | http://link.springer.com/article/10.1186/s42155-019-0051-7 |
| work_keys_str_mv | AT massimoventurini transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT carolinalanza transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT paolomarra transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT annacolarieti transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT martapanzeri transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT luigiaugello transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT simonegusmini transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT marcosalvioni transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT francescodecobelli transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients AT alessandrodelmaschio transcatheterembolizationwithsquidcombinedwithotherembolicagentsoraloneindifferentabdominaldiseasesasinglecenterexperiencein30patients |